Wil Helmus schreef op 7 februari 2021 10:11:
Endra Life Sciences NDRA. Hebben afgelopen juni goedkeuring aangevraagd voor TAEUS. De FDA geeft normaal binnen 8 mnd uitsluitsel. TAEUS is een diagnostisch ultrasoon apparaat om leverziekte te detecteren. Ik pluk dit van Stocktwits:
*Small $68M market cap, 33M shares outstanding, No Toxic Financing, No Reverse Splits
*Worldwide ultrasound market growing low double digits, much stronger than CT or MRI *TAEUS is Euro CE Mark approved, likely FDA 510k approval is imminent, 50X cheaper than MRI
*Experienced GE alum management team
*GE Healthcare, $NDRA partner, has 30%+ of ultrasound market, believes in TAEUS & will help with sales.
*1Billion++ patients with fatty liver disease, TAEUS is the first diagnostic product to market addressing liver disease 2 Full Stages ahead of current tech.
*Future TAEUS applications visualize tissue temperature & function *Pharma companies desperately need TAEUS technology for their drug studies.
*Multiple potential revenue streams: software, services, supplies & licensing deals with OEMs, TAEUS pricing $50k per unit.
*80+ IP assets, NDRA has Patent Agent embedded on their engineering team.
*Burn rate low with NDRA's "light asset model"
*CriTech Research designed the TAEUS platform software for $NDRA. From the CriTech website: " Our work has a 100% first-time acceptance rate from FDA."
Ik ga normaal liever voor safe, maar dit klinkt wel aantrekkelijk om een kleine positie in te nemen. Iemand een mening hierover?